Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | REN | P00797 | 11/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL292188 | 0.89 | P2RX7 (0.43) | SLC6A2SLC6A4SLC6A3P2RX7 | |
| SCHEMBL293416 | 0.86 | MAPT (0.48) | SLC6A2SLC6A4SLC6A3HTR1AADRA1B | |
| SCHEMBL291498 | 0.86 | AR (0.42) | RENHTR1AADRA1AADRA1BAR | |
| SCHEMBL292828 | 0.85 | HTR7 (0.40) | RENARP2RX7HTR7 | |
| SCHEMBL292608 | 0.83 | AR (0.39) | HTR1AADRA1AADRA1BARP2RX7 | |
| SCHEMBL291908 | 0.82 | HTR7 (0.40) | ARP2RX7HTR7MAPT | |
| SCHEMBL292465 | 0.82 | FFAR4 (0.39) | SLC6A2SLC6A4SLC6A3REN | |
| SCHEMBL292679 | 0.80 | HSD11B1 (0.46) | RENHTR1AMAPT | |
| SCHEMBL292093 | 0.80 | AR (0.41) | SLC6A2SLC6A4SLC6A3ADRA1AADRA1B | |
| SCHEMBL292232 | 0.78 | AR (0.36) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158790-B2 | Cyclic amine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2036896-B1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| WO-2011065519-A1 | SUBSTITUTED OXOPIPERAZINE COMPOUND | 第一三共株式会社 (JP) | 2011-06-03 | — | — | WO | disclosed |
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2036896-A1 | CYCLIC AMINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | HRH3, HRH4, H1-0 | SLC6A2 411/4885SLC6A4 834/4885SLC6A3 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.